What are the safety profiles of Argatroban and DAPT when used together for managing early neurological deterioration (END) following stroke?
Label:chem
Topic
The safety of using Argatroban in combination with DAPT is crucial for its clinical application. Potential concerns include the risk of bleeding and other complications such as liver or kidney dysfunction.
From: "Argatroban plus dual antiplatelet therapy: Preliminary evidence for managing early neurological deterioration after lacunar stroke", Clinical Neurology and Neurosurgery, Volume 250, March 2025, 108786
Answer
The combination of Argatroban and DAPT demonstrated a favorable safety profile. No serious bleeding events or organ-related complications were observed during the treatment period. Only one case of mild gingival bleeding was reported in the Argatroban group, which resolved spontaneously without intervention. APTT values in the Argatroban group fluctuated within the clinically acceptable range, indicating effective anticoagulation without compromising safety.
Return to Home
Chemical List
Knowledge you may be interested in